Three articles present genetic evidence for molecular mechanisms underlying specific clinical phenomena: cognitive dysfunction in schizophrenia, responsiveness to antipsychotic drugs, and mania as the presenting feature of bipolar disorder. Hirvonen et al. (p.
1747) demonstrated a genetic influence on dopamine transmission in the prefrontal cortex, which is related to cognitive deficits in schizophrenia. The unaffected monozygotic twins in pairs discordant for schizophrenia had higher densities of dopamine D
1 receptors in the medial prefrontal cortex than healthy comparison subjects. This twin strategy allowed researchers to assess a genetic abnormality in dopamine receptors, free of the confounding effects of antipsychotic medication. Among patients receiving antipsychotic drugs, Reynolds et al. (p.
1826) found that one of three possible genotypes for a variable region of the serotonin 5-HT
1A receptor gene was associated with greater improvement in negative and depressive symptoms than were the other two genotypes. Kassem et al. (p.
1754) report that manic onset of bipolar disorder is linked to chromosome 16p and that the polarity of the first episode (manic or depressive) is transmitted in families. A postmortem study by Paz et al. (p.
1829) presents evidence for cerebellar hyperactivity based on mRNA levels of three activity-dependent genes. As Kendler and Greenspan (p.
1683) describe, the genetic underpinnings of psychiatric illness have several commonalities with the genetics of behavior in "simpler" organisms, such as fruit flies and rodents. The editorial by Drs. David Lewis and Ahmad Hariri (p.
1676) provides further perspective on the field of psychiatric genetics.